The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors - Contacts and Locations

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

This study has been terminated.

Study NCT00002418. Last updated on August 13, 2008. Information provided by Bristol-Myers Squibb

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002418

Locations


United States, California
	Pacific Oaks Med Group
	Beverly Hills, California, United States, 90211

United States, Colorado
	Univ of Colorado / Health Science Ctr
	Denver, Colorado, United States, 80262

United States, Georgia
	AIDS Research Consortium of Atlanta
	Atlanta, Georgia, United States, 30308

United States, Rhode Island
	Brown Univ School of Medicine
	Providence, Rhode Island, United States, 02908

United States, Virginia
	Hampton Roads Med Specialists
	Hampton, Virginia, United States, 23666

Sponsors and Collaborators

Bristol-Myers Squibb

Boehringer Ingelheim Pharmaceuticals

Triangle Pharmaceuticals